An open-label, single-dose, three-treatment, three-period study to investigate the effect of SLCO2B1 genotype and apple juice on pharmacokinetics of atenolol after oral administration in healthy male Korean.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Atenolol oral administration
Atenolol oral administration with apple juice 1200 mL
Atenolol oral administration with apple juice 600 mL
Seoul National University Hospital
Seoul, South Korea
AUC of atenolol according to the SLCO2B1 genotypes
The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration, as calculated by the linear/log trapezoidal method will be summarized by treatment and genotype group using descriptive statistics.
Time frame: 0-48 hr after drug administration
Blood pressure of the subjects who administered atenolol according to the SLCO2B1 genotypes
Blood pressure measurement will be presented as descriptive statistics for the difference from baseline where appropriate.
Time frame: 0-48 hr after drug admnistration
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Number of participants with adverse event as a measure of safety and tolerability \*Measure of safety and tolerability: physical examinations, ECG, Laboratory tests (including hematology, chemistry, urinalysis) \- Descriptive statistics will be calculated for quantitative safety data as well as for the difference from baseline where appropriate.
Time frame: 0-48 hr after drug admnistration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.